NO20014491D0 - Fremgangsmåte - Google Patents

Fremgangsmåte

Info

Publication number: NO20014491D0
Authority: NO; Norway
Prior art keywords: cell; antigenic molecule; stimulating; approach; immune response
Prior art date: 1999-03-15

Application number

NO20014491A

Other languages

English (en)

Other versions

NO331101B1 (no

NO20014491L (no

Inventor

Kristian Berg

Torunn E Tjelle

Anders Hoegsetm

Lina Prasmickaite

Original Assignee

Photocure Asa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-03-15

Filing date

2001-09-14

Publication date

2001-09-14

2001-09-14 Application filed by Photocure Asa filed Critical Photocure Asa

2001-09-14 Publication of NO20014491D0 publication Critical patent/NO20014491D0/no

2001-11-14 Publication of NO20014491L publication Critical patent/NO20014491L/no

2011-10-03 Publication of NO331101B1 publication Critical patent/NO331101B1/no

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5152—Tumor cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Genetics & Genomics (AREA)
Microbiology (AREA)
Immunology (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Biotechnology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oncology (AREA)
Epidemiology (AREA)
Mycology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Engineering & Computer Science (AREA)
Biochemistry (AREA)
Cell Biology (AREA)
Pathology (AREA)
Radiology & Medical Imaging (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Neurology (AREA)
Virology (AREA)
Neurosurgery (AREA)
Communicable Diseases (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO20014491A 1999-03-15 2001-09-14 In vitro-fremgangsmate for a uttrykke et antigenmolekyl og antigenmolekyl og et fotosensibiliserende middel for anvendelse ved uttrykking av antigenmolekylet. NO331101B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9905911.5A GB9905911D0 (en)	1999-03-15	1999-03-15	Method
PCT/GB2000/000903 WO2000054802A2 (en)	1999-03-15	2000-03-10	Method of expressing antigens on the surface of antigen presenting cells by photochemical internalization

Publications (3)

Publication Number	Publication Date
NO20014491D0 true NO20014491D0 (no)	2001-09-14
NO20014491L NO20014491L (no)	2001-11-14
NO331101B1 NO331101B1 (no)	2011-10-03

Family

ID=10849643

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20014491A NO331101B1 (no)	1999-03-15	2001-09-14	In vitro-fremgangsmate for a uttrykke et antigenmolekyl og antigenmolekyl og et fotosensibiliserende middel for anvendelse ved uttrykking av antigenmolekylet.

Country Status (19)

Country	Link
US (2)	US8216587B1 (no)
EP (1)	EP1223973B1 (no)
JP (1)	JP4922490B2 (no)
KR (1)	KR100769113B1 (no)
CN (1)	CN100379450C (no)
AT (1)	ATE419866T1 (no)
AU (1)	AU771990B2 (no)
CA (1)	CA2367357C (no)
CZ (1)	CZ299370B6 (no)
DE (1)	DE60041347D1 (no)
DK (1)	DK1223973T3 (no)
ES (1)	ES2319255T3 (no)
GB (1)	GB9905911D0 (no)
HU (1)	HU227604B1 (no)
MX (1)	MXPA01009316A (no)
NO (1)	NO331101B1 (no)
NZ (1)	NZ514228A (no)
PL (1)	PL208221B1 (no)
WO (1)	WO2000054802A2 (no)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CZ303792B6 (cs)	2000-11-29	2013-05-09	Pci Biotech As	Zpusob zavedení molekuly do bunky
AU2002220853B2 (en)	2000-11-29	2007-06-28	Pci Biotech As	Photochemical internalization for delivery of molecules into the cytosol
AU2002250034A1 (en) *	2001-02-08	2002-08-19	Sequitur, Inc.	Methods of light activated release 0f ligands from endosomes
GB0121023D0 (en)	2001-08-30	2001-10-24	Norwegian Radium Hospital Res	Compound
US20060009409A1 (en)	2002-02-01	2006-01-12	Woolf Tod M	Double-stranded oligonucleotides
EP2128248B2 (en)	2002-02-01	2017-01-11	Life Technologies Corporation	Oligonucleotide compositions with enhanced efficiency
GB0613753D0 (en)	2006-07-11	2006-08-23	Norwegian Radium Hospital Res	Method
AU2007307206B2 (en)	2006-10-04	2016-02-11	Janssen Pharmaceutica, N.V.	Preparation of inactivated artificial antigen presenting cells and their use in cell therapies
GB0811955D0 (en) *	2008-06-30	2008-07-30	Pci Biotech As	Method
GB0914287D0 (en)	2009-08-14	2009-09-30	Pci Biotech As	Compositions
GB0914286D0 (en) *	2009-08-14	2009-09-30	Pci Biotech As	Method
GB201208548D0 (en) *	2012-05-15	2012-06-27	Pci Biotech As	Compound and method
US20160040128A1 (en) *	2013-03-15	2016-02-11	Pci Biotech As	Method
GB2517707B (en)	2013-08-28	2020-09-02	Pci Biotech As	A device for light-induced rupture of endocytic vesicles to effect the delivery of an antigen
WO2015028575A1 (en) *	2013-08-28	2015-03-05	Pci Biotech As	Immunisation method by photochemical internalisation
CA2922320C (en) *	2013-08-28	2022-11-22	Pci Biotech As	Enhanced photochemical internalisation using a tlr ligand
WO2015154832A1 (en)	2014-04-11	2015-10-15	Pci Biotech As	Method of treating melanoma
GB201415250D0 (en) *	2014-08-28	2014-10-15	Pci Biotech As	Compound and method
KR102678732B1 (ko)	2014-08-28	2024-06-25	피씨아이 바이오테크 에이에스	화합물 및 방법
GB201503776D0 (en)	2015-03-05	2015-04-22	Pci Biotech As	Compound and method
KR20190068573A (ko)	2016-10-14	2019-06-18	피씨아이 바이오테크 에이에스	젬시타빈의 tpcs-2a 유도된 광화학 내재화로의 담관암의 치료
CN107029236B (zh) *	2017-04-18	2020-04-10	中国医学科学院生物医学工程研究所	一种吲哚菁绿自组装纳米疫苗及制备方法
CN107217041B (zh) *	2017-07-11	2020-05-15	深圳华云生物技术有限公司	具有高抗原呈递的dc细胞和抗原特异性t细胞及其制备方法和应用
GB201718631D0 (en)	2017-11-10	2017-12-27	Pci Biotech As	Method
GB201801169D0 (en)	2018-01-24	2018-03-07	Pci Biotech As	Method
WO2020017962A1 (en)	2018-07-16	2020-01-23	Dcprime B.V.	A combination product for use in tumor vaccination.
US11052144B2 (en)	2019-04-25	2021-07-06	Dcprime B.V.	Methods of tumor vaccination
CA3172447A1 (en)	2020-03-27	2021-09-30	Erik Hans MANTING	In vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
AU2021243864A1 (en)	2020-03-27	2022-11-03	Mendus B.V.	Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
CA3182607A1 (en)	2020-06-30	2022-01-06	Erik Hans MANTING	Use of leukemia-derived cells in ovarian cancer vaccines
AU2022211682A1 (en)	2021-01-22	2023-08-03	Mendus B.V.	Methods of tumor vaccination
GB202101726D0 (en)	2021-02-08	2021-03-24	Pci Biotech As	Method
GB202115451D0 (en)	2021-10-27	2021-12-08	Pci Biotech As	Method
GB202301312D0 (en)	2023-01-30	2023-03-15	Pci Biotech As	Method and product

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5258453A (en)	1992-01-21	1993-11-02	University Of Utah	Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light
US20020168374A1 (en) *	1992-08-07	2002-11-14	Ralph T. Kubo	Hla binding peptides and their uses
US5820872A (en)	1992-11-18	1998-10-13	Yale University	Methods and compositions for improving the effectiveness of X-irradiation therapy for the treatment of an internal solid tumor
US5651993A (en) *	1992-11-18	1997-07-29	Yale University	Specific immune system modulation
NO180167C (no) *	1994-09-08	1997-02-26	Photocure As	Fotokjemisk fremgangsmåte til å innföre molekyler i cellers cytosol
US6008211A (en) *	1995-07-27	1999-12-28	Pdt Pharmaceuticals, Inc.	Photoactivatable compounds comprising benzochlorin and furocoumarin
DE69803376T2 (de) *	1997-05-07	2002-08-14	Qlt Inc., Vancouver	Äthylenglykolester von monohydrobenzoporphyrinderivaten als photoaktive mittel
AU2002220853B2 (en)	2000-11-29	2007-06-28	Pci Biotech As	Photochemical internalization for delivery of molecules into the cytosol
GB201208548D0 (en)	2012-05-15	2012-06-27	Pci Biotech As	Compound and method
CA2922320C (en)	2013-08-28	2022-11-22	Pci Biotech As	Enhanced photochemical internalisation using a tlr ligand

1999
- 1999-03-15 GB GBGB9905911.5A patent/GB9905911D0/en not_active Ceased
2000
- 2000-03-10 MX MXPA01009316A patent/MXPA01009316A/es active IP Right Grant
- 2000-03-10 NZ NZ514228A patent/NZ514228A/xx not_active IP Right Cessation
- 2000-03-10 ES ES00909489T patent/ES2319255T3/es not_active Expired - Lifetime
- 2000-03-10 EP EP00909489A patent/EP1223973B1/en not_active Expired - Lifetime
- 2000-03-10 PL PL355015A patent/PL208221B1/pl unknown
- 2000-03-10 AT AT00909489T patent/ATE419866T1/de active
- 2000-03-10 HU HU0202441A patent/HU227604B1/hu not_active IP Right Cessation
- 2000-03-10 CZ CZ20013328A patent/CZ299370B6/cs not_active IP Right Cessation
- 2000-03-10 JP JP2000604874A patent/JP4922490B2/ja not_active Expired - Lifetime
- 2000-03-10 KR KR1020017011688A patent/KR100769113B1/ko not_active Expired - Fee Related
- 2000-03-10 CA CA2367357A patent/CA2367357C/en not_active Expired - Lifetime
- 2000-03-10 US US09/524,454 patent/US8216587B1/en not_active Expired - Fee Related
- 2000-03-10 DE DE60041347T patent/DE60041347D1/de not_active Expired - Lifetime
- 2000-03-10 CN CNB008050848A patent/CN100379450C/zh not_active Expired - Lifetime
- 2000-03-10 DK DK00909489T patent/DK1223973T3/da active
- 2000-03-10 WO PCT/GB2000/000903 patent/WO2000054802A2/en not_active Ceased
- 2000-03-10 AU AU31771/00A patent/AU771990B2/en not_active Ceased
2001
- 2001-09-14 NO NO20014491A patent/NO331101B1/no not_active IP Right Cessation
2012
- 2012-07-05 US US13/542,017 patent/US9737594B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
HUP0202441A3 (en)	2004-07-28
AU3177100A (en)	2000-10-04
PL355015A1 (en)	2004-03-22
WO2000054802A3 (en)	2002-05-10
EP1223973A2 (en)	2002-07-24
NZ514228A (en)	2004-01-30
KR100769113B1 (ko)	2007-10-22
NO331101B1 (no)	2011-10-03
EP1223973B1 (en)	2009-01-07
US8216587B1 (en)	2012-07-10
JP2002541072A (ja)	2002-12-03
ATE419866T1 (de)	2009-01-15
DE60041347D1 (de)	2009-02-26
US9737594B2 (en)	2017-08-22
CN100379450C (zh)	2008-04-09
KR20010110664A (ko)	2001-12-13
AU771990B2 (en)	2004-04-08
GB9905911D0 (en)	1999-05-05
PL208221B1 (pl)	2011-03-31
JP4922490B2 (ja)	2012-04-25
NO20014491L (no)	2001-11-14
US20130330363A1 (en)	2013-12-12
CA2367357C (en)	2015-01-06
HU227604B1 (en)	2011-09-28
WO2000054802A2 (en)	2000-09-21
MXPA01009316A (es)	2003-07-14
CZ299370B6 (cs)	2008-07-09
HUP0202441A2 (en)	2002-10-28
CN1376073A (zh)	2002-10-23
CZ20013328A3 (cs)	2002-03-13
DK1223973T3 (da)	2009-05-04
ES2319255T3 (es)	2009-05-06
CA2367357A1 (en)	2000-09-21

Publication	Publication Date	Title
NO20014491D0 (no)	2001-09-14	Fremgangsmåte
BR0015501A (pt)	2003-02-25	Compostos de aminoalquil glucosaminida fosfato e uso dos mesmos como adjuvantes e agentes de efeito imune
CY1120070T1 (el)	2018-12-12	Μεθοδοi θεραπευτικης αγωγης με τη χρηση συζευγματων αντισωματος εναντι-erbb-μεϋτανσινοειδους
ATE355079T1 (de)	2006-03-15	Behandlung von prostata-krebs mit anti-erbb2 antikörpern
ATE163195T1 (de)	1998-02-15	Lösliche liganden für cd40
DE60033530D1 (de)	2007-04-05	Humane antikörper gegen ctla-4 und deren verwendungen
BR0207775A (pt)	2004-03-30	Lipossomos anfotéricos métodos para carregamento dos mesmos com ingredientes ativos e sua utilização
ATE404587T1 (de)	2008-08-15	Verfahren zur identifizierung von induktoren und inhibitoren proteolytischer antikörper, zusammensetzungen sowie deren verwendungen
TR199902124T2 (xx)	2000-06-21	�ltihapl� hastal�klar�n tedavisinde yararl� k��k molek�ller.
BR0015611A (pt)	2002-07-16	Processo de limpeza que utiliza ondas ultra-sÈnicas
PT1157041E (pt)	2005-10-31	Anticorpos para terapia e diagnostico de cancro
DE69818096D1 (de)	2003-10-16	Cyaninfarbstoffe
EA200000349A1 (ru)	2000-10-30	Способ лечения оппозиционного расстройства
BR0115121A (pt)	2003-09-30	Compostos n-((1,2,4)triazoloazinil)tiofenossulfonamida como herbicidas
NL174949C (nl)	1984-09-03	Enzym-immobiliserende drager, werkwijze voor het bereiden ervan alsmede werkwijze voor het immobiliseren van een enzym onder toepassing van een dergelijke drager.
SE8900835D0 (sv)	1989-03-09	Improvement in or relating to organic compounds
DK1037642T3 (da)	2009-07-06	Modificerede polysaccharider med ændret biologisk genkendelse
DK192890D0 (da)	1990-08-14	24r-scumnol, fremgangsmaade til fremstilling heraf samt anvendelse af samme
DE602005007177D1 (de)	2008-07-10	Komplexe mit adjuvanter wirkung
DE59611293D1 (de)	2005-12-15	Protein mit dnase-aktivität
ATE145335T1 (de)	1996-12-15	Kreuzreaktive immunisierung gegen influenza
FI890309A0 (fi)	1989-01-20	Parannettu menetelmä tiotepan valmistamiseksi
ATE420104T1 (de)	2009-01-15	Antigen
ATE242189T1 (de)	2003-06-15	Verfahren zum erhöhen der festigkeit eines porösen körpers
SE0303434D0 (sv)	2003-12-19	Förfarande för underlättande av applicering av en absorberande artikel på en användare samt tillhörande artikel appliceringshjälpmedel

Legal Events

Date	Code	Title	Description
2018-10-22	MM1K	Lapsed by not paying the annual fees